Sandor Schokker
4PUBLICATIONS
16CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (4)
Sort by Publication Date:
|Mar 06, 2021
A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX.Charlotte I Stroes, Sandor Schokker, Remco J Molenaar
|Jan 28, 2021
Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT).Tom van den Ende, Nicolien C de Clercq, Mark I van Berge Henegouwen
|Aug 04, 2020
Development and validation of an LC-MS/MS method for simultaneous quantification of co-administered trastuzumab and pertuzumab.Sandor Schokker, Fabrizia Fusetti, Francesco Bonardi
|Jun 19, 2019
Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study).Sandor Schokker, Stephanie O van der Woude, Jessy Joy van Kleef
Pageof 1
Frequent Collaborators
2 joint publications
Mark I van Berge Henegouwen
2 joint publications
Jelle P Ruurda
1 joint publications
Jessy Joy van Kleef
1 joint publications
Ludo F M Beenen
1 joint publications
Maarten F Bijlsma
1 joint publications
Hanneke W M van Laarhoven
1 joint publications
Tom van den Ende
1 joint publications
Suzanne S Gisbertz
1 joint publications
Richard van Hillegersberg
1 joint publications
Tanya T D Soeratram
